Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends
This article was originally published in BioPharma Dive.
Pharma companies are increasingly turning to real-world data to answer their commercial business questions, but not all realize that unstructured EMR data…
As therapies have become more complex, pharma companies are now challenged to achieve precision targeting within a much tighter timeframe. While claims data is readily available, one of its key…
For years, pharma commercialization strategies focused only on traditional market access data: payer policies and restrictions. While payer coverage is still essential information, this single-source approach cannot help manufacturers identify…
In recent years, pharma companies have begun to embrace lab data as a richly rewarding dataset for a whole host of purposes, including trial enrollment and site identification, patient monitoring…
This article was originally published in Drug Channels.
In a competitive market, pharma companies are increasingly relying on various datasets to drive their decision-making. With so many disparate sources, however,…
To fully understand how payers impact patient access, pharma companies should be evaluating payers using multiple datasets, including both coverage/restriction data and claims data. While payer policies indicate how payers…
Lab data has become an increasingly essential dataset for pharmaceutical companies at all stages of the product life cycle. A key use case for our MMIT clients is using lab…
In the complex healthcare analytics landscape, understanding the nuances of open and closed claims is critical for researchers and analysts. Open and closed claims each offer unique insights into the…
Our first post in this series discussed how early market access research, conducted in the 12-18 months before launch, helps pharma companies identify differentiators and establish accurate expectations.
As your…
This article was originally published in BioPharma Dive.
For years, many manufacturers have assumed that pre-market physician education was not strictly necessary unless their brand was the first to market…
